Yamazaki, N., Takenouchi, T., Fujimoto, M., Ihn, H., Uchi, H., Inozume, T., . . . Yokota, K. (2017). Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother Pharmacol.
Citação norma ChicagoYamazaki, Naoya, et al. "Phase 1b Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Japanese Patients With Advanced Melanoma (KEYNOTE-041)." Cancer Chemother Pharmacol 2017.
Citação norma MLAYamazaki, Naoya, et al. "Phase 1b Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Japanese Patients With Advanced Melanoma (KEYNOTE-041)." Cancer Chemother Pharmacol 2017.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.